TrioBiotics Pharma AG
Triton BioPharma AG names Mark Hamann as Chief Scientific Officer
Triton Biopharma AG / Change of Personnel Release of a Corporate News, transmitted by DGAP - a company of EquityStory AG. The issuer / publisher is solely responsible for the content of this announcement. ---------------------------------------------------------------------- Zug, Switzerland – February 2nd, 2009 – TRITON BIOPHARMA AG (Frankfurt: 4ON) today announced the appointment of Dr. Mark T. Hamann, Ph.D. as Chief Scientific Officer of Triton BioPharma AG. In addition to his appointment as CSO, Dr. Hamann is a co-founder and director of Triton BioPharma AG and holds a full-time position as a Professor of Pharmacognosy, Pharmacology, Pharmacy Practice, Chemistry & Biochemistry at the University of Mississippi. Dr. Hamann is also a Research Professor with the National Center for Natural Products Research at the University of Mississippi and an Adjunct Professor with the Center of Marine Biotechnology (COMB), University of Maryland Biotechnology Institute (UMBI). He has several years experience in GMP pharmaceutical manufacturing and twenty years marine natural products research. Dr. Hamann completed a Ph.D. degree in Marine Natural Products Chemistry in 1992 at the University of Hawaii, Chemistry Department under the guidance of the late Professor Paul Scheuer -a pioneer in the discovery and chemical ecology of marine natural products. His research program at the University of Mississippi, Department of Pharmacognosy & Pharmacology, is focused on the characterization of prototype drug-leads from chemically defended marine organisms. Dr. Hamann’s vast experience includes an extensive array of collaborations with the Pharmaceutical and Biotechnology industry, including projects funded by National Institutes of Health, The World Health Organization, Medicines for Malaria Venture, The Environmental Protection Agency (EPA), NASA, the National SeaGrant Programs (NOAA) and International Visiting Scholar Programs focused on the development of treatments for infectious, neurological diseases and cancer from marine derived secondary metabolites. He has served as the principal investigator on more than 10 research projects over the past ten years totaling over $6 million in funded research support, in addition to directing the chemistry core of the NIH funded ($11 million) Center for Neuropharmacology. During his 20-year research career, Dr. Hamann has published 120 scientific papers, reviews and book chapters. He also serves as an associate editor for Biochimica and Biophysica Acta. Dr. Hamann has received numerous awards and honors, organized numerous scientific symposia and meetings and frequently delivers keynote or plenary presentations at international conferences. 'I am very excited to serve in the role of CSO, working with Triton’s team of researchers in the area of marine natural products development and new drug discovery,' said Dr. Hamann. 'I believe we have compiled an exceptional group of scientists and consultants to advance the novel drug leads in our current pipeline.' About Triton BioPharma AG Triton BioPharma AG is a holding company and is only active through its wholly-owned subsidiaries, Triton BioPharma SARL and Triton BioPharma LLC. These subsidiary companies are responsible for all of Triton’s biotechnology operations and R&D activities in the discovery, development, and commercialization of novel drug leads from marine sources for the global market. Triton’s current pipeline includes advanced preclinical candidates in the treatment of neuropsychiatric disorders, including depression and anxiety, inflammation, infectious diseases and cancer. The company was founded in 2008 and has its corporate office in Toronto, Canada. Contact: Investor Relations Europe: Milestone Media AG, Zug (Switzerland) Phone: +41 (0)41 5000 769 Fax: +41 (0)41 5000 728 E-mail: info@milestonemedia.ch For more information, visit www.tritonbiopharma.com 02.02.2009 Financial News transmitted by DGAP ----------------------------------------------------------------------
Aktuelle News
Aktuelle Berichte
Keine Berichte gefunden
Anstehende Events
Keine Events gefunden
Webcasts
Keine Webcasts gefunden